Breakthrough T1D Board Shakeup Signals Focus on Innovation Amidst Therapy Advances
Event summary
- Karen Shishino Jordan has been named Chair of Breakthrough T1D’s International Board of Directors (IBOD), succeeding an unnamed predecessor.
- Carlton McMillan has been appointed Vice Chair of the IBOD, alongside Jordan.
- Jordan, who was diagnosed with T1D in 2023, previously held leadership roles including Finance and Investment Committee Chair.
- McMillan, whose wife was diagnosed with T1D at age five, spearheaded a corporate partnership between Airbnb and Breakthrough T1D.
- Both appointments occur during a period of accelerating scientific progress in T1D therapies.
The big picture
The leadership transition at Breakthrough T1D coincides with a period of rapid innovation in T1D therapies, including potential cures and preventative measures. The appointments of Jordan and McMillan, both with deep personal and professional connections to the disease, signal a strategic emphasis on financial discipline and expanded partnerships to capitalize on this momentum. The organization's influence extends globally, impacting millions of individuals and driving significant research funding.
What we're watching
- Governance Dynamics
- Jordan’s dual experience as a T1D patient and finance expert suggests a heightened focus on financial stewardship and patient-centric research priorities.
- Partnership Strategy
- McMillan’s prior success with Airbnb indicates a potential shift towards more robust corporate partnerships to expand fundraising and awareness efforts.
- Research Alignment
- The board’s focus on a ‘golden age of advanced medicine’ implies increased scrutiny of research investments and a potential acceleration of clinical trial timelines.
Related topics